Establishing Precompetitive Collaborations to Stimulate Genomics-Driven Drug Development: Workshop Summary

✍ Scribed by Roundtable on Translating Genomic-Based Research on Health, Institute of Medicine

Publisher: National Academies Press
Year: 2011
Tongue: English
Leaves: 91
Category: Library

No coin nor oath required. For personal study only.

✦ Synopsis

Despite the many basic research discoveries in genetics, relatively few gene-based treatments, drugs, or preventative measures have been developed. One way to bridge this gap may be for industry, academia, and government to develop partnerships that share resources while distributing risk. However, intellectual property protections and other barriers can inhibit collaborative efforts. The Institute of Medicine held a workshop on July 22, 2010, to explore these issues and develop solutions.--Publisher's description.

✦ Table of Contents

Cover......Page 1
Appendix B: Speaker Biographical Sketches......Page 0
Copyright......Page 3
Reviewers......Page 10
Acknowledgments......Page 12
Contents......Page 14
Abbreviations and Acronyms......Page 16

📜 SIMILAR VOLUMES

Extending the Spectrum of Precompetitive

📁 Extending the Spectrum of Precompetitive Collaboration in Oncology Research: Workshop Summary

✍ Margie Patlak, Sharyl J. Nass, and Erin Balogh (eds.); Institute of Medicine 📂 Library 📅 2010 🏛 National Academies Press 🌐 English

Despite spending more time and money in developing novel therapeutics, the success rate for new pharmacologic treatments has been poor. Although the research and development expenditures have grown 13 percent each year since 1970 (a 50-fold increase), the number of new drugs approved annually is no

Genome-Based Therapeutics: Targeted Drug

📁 Genome-Based Therapeutics: Targeted Drug Discovery and Development: Workshop Summary

✍ Institute Of Medicine, Board On Health Sciences Policy, Roundtable on Translatin 📂 Library 📅 2012 🏛 NATL ACADEMY PR 🌐 English

<p>The number of new drug approvals has remained reasonably steady for the past 50 years at around 20 to 30 per year, while at the same time the total spending on health-related research and development has tripled since 1990. There are many suspected causes for this trend, including increases in re

Addressing the Barriers to Pediatric Dru

📁 Addressing the Barriers to Pediatric Drug Development: Workshop Summary

✍ Development, and Translation Forum on Drug Discovery, Institute of Medicine 📂 Library 📅 2008 🌐 English

Building a National Framework for the Es

📁 Building a National Framework for the Establishment of Regulatory Science for Drug Development: Workshop Summary

✍ Institute of Medicine; Board on Health Sciences Policy; and Translation Developm 📂 Library 📅 2011 🏛 National Academies Press 🌐 English

The Food and Drug Administration (FDA) is tasked with ensuring the safety and effectiveness of medicine. FDA's science base must be strong enough to make certain that regulatory decisions are based on the best scientific evidence. The IOM held a public workshop on February 26, 2010, to examine the s

Generating Evidence for Genomic Diagnost

📁 Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary

✍ Roundtable on Translating Genomic-Based Research for Health, theresa Wizemann, I 📂 Library 📅 2011 🏛 The National Academies Press 🌐 English

Ten years after the sequencing of the human genome, scientists have developed genetic tests that can predict a person's response to certain drugs, estimate the risk of developing Alzheimer's disease, and make other predictions based on known links between genes and diseases. However, genetic tests h

Accelerating the Development of Biomarke

📁 Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary

✍ Development, and Translation Forum on Drug Discovery, Institute of Medicine 📂 Library 📅 2009 🏛 National Academies Press 🌐 English

Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a